Tag: report

The latest market research report highlights significant growth in the seed coating market driven by factors like rising demand for low-cost crop protection and technological advancements. Key players such as BASF SE and Cistronics Innovations are pivotal in this sector. Polymers lead the market due to their enhanced protection and adherence qualities. The cereals & grains segment dominates, primarily driven by the global demand for increased productivity. Asia-Pacific shows the fastest growth, fueled by agricultural expansion and modern farming adoption. This comprehensive report offers in-depth analysis on materials, active ingredients, and regional growth trends, catering to manufacturers and stakeholders aiming for strategic growth in the seed coating industry.

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

(Oslo, 22. juli 2025) – Statkraft leverte sterkt driftsresultat i andre kvartal 2025, tross lavere priser, spesielt i de nordlige prisområdene i Norge og Sverige. Resultatet ble negativt påvirket av nedskrivninger, hovedsakelig på grunn av forventinger om lavere kraftpriser i enkelte regioner, samt valutaeffekter. Statkraft refokuserer for fortsatt lønnsom vekst.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Naphthalene Sulfonate Market size & share revenue was valued at approximately USD 813.20 Million in 2024 and is expected to reach USD 841.78 Million in 2025 and is expected to reach around USD 1,113.50 Million by 2034, at a CAGR of 3.16% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Acar Kimya, Akzo Nobel N.V., BASF SE, Enaspol, GCP Applied Technologies Inc., Giovanni Bozzetto S.p.A., Himadri Speciality Chemical Limited, Hunstman International LLC, Kao Corporation, Koppers Inc., MUHU (China) Construction Materials Company Limited, Nease Performance Chemicals, PCC SE, Arkema Group, and Eastman Chemical Company and others.

VANCOUVER, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) -- ERAG Energie & Rohstoff AG PCC (the “Acquiror), a private investment a private investment holding company incorporated in Liechtenstein, announces that on July 17, 2025, the Acquiror, along with two joint actors HMS Bergbau AG (“HMS”) and LaVo Verwaltungsgesellschaft MBH (“LaVo”), acquired Common Shares of Belmont Resources Inc. (TSX-V: BEA) (the “Issuer”). The Issuer completed a private placement of Common Shares, issuing a total of 26,300,00 shares at a price of $0.045 per share for proceeds of $1,183,500 (the “Private Placement”). Under the Private Placement, the Acquiror purchased 4,000,000 Common Shares, HMS purchased 15,000,000 Common Shares and LaVo purchased 7,300,000 Common Shares.

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.